Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA.

Clin Cancer Res. 2012 Sep 15;18(18):5031-42. doi: 10.1158/1078-0432.CCR-12-0453. Epub 2012 Jul 24.

PMID:
22829202
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.

Kirane A, Toombs JE, Larsen JE, Ostapoff KT, Meshaw KR, Zaknoen S, Brekken RA, Burrows FJ.

Carcinogenesis. 2012 Sep;33(9):1639-46. doi: 10.1093/carcin/bgs195. Epub 2012 Jun 7.

PMID:
22678114
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Intraduodenal sarcoma recurrence of retroperitoneal origin: an unusual cause for a duodenal obstruction.

Bao JJ, Mansour JC, Timmerman RD, Kirane A, Ewing GE, Schwarz RE.

World J Surg Oncol. 2012 Apr 20;10:59. doi: 10.1186/1477-7819-10-59.

PMID:
22520024
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.

Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE.

BMC Cancer. 2011 Jan 12;11:15. doi: 10.1186/1471-2407-11-15.

PMID:
21226944
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk